<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Научные результаты биомедицинских исследований</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2658-6533-2026-12-1-0-9</article-id><article-id pub-id-type="publisher-id">4042</article-id><article-categories><subj-group subj-group-type="heading"><subject>Клиническая медицина</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Возрастные диагностические и дефицитарные особенности пациентов&amp;nbsp;&lt;/strong&gt;&lt;strong&gt;с метаболически-ассоциированной жировой болезнью печени&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Age-related diagnostic and deficiency features patients with metabolic-associated fatty liver disease&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Кляритская</surname><given-names>Ирина Львовна</given-names></name><name xml:lang="en"><surname>Klaritskaya</surname><given-names>Irina L.</given-names></name></name-alternatives><email>klira3@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Бондарь</surname><given-names>Кристина Геннадьевна</given-names></name><name xml:lang="en"><surname>Bondar</surname><given-names>Kristina G.</given-names></name></name-alternatives><email>giletan@mail.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2026</year></pub-date><volume>12</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2026/1/Биомед_исследования-140-154.pdf" /><abstract xml:lang="ru"><p>Актуальность: В связи с увеличением доли пожилого населения и нерациональных стереотипов питания повышается распространённость метаболически-ассоциированной жировой болезни печени (МАЖБП), развитие которой может способствовать ухудшению гериатрического статуса таких пациентов. Однако возрастные диагностические и дефицитарные особенности МАЖБП в настоящее время недостаточно изучены и противоречивы. Цель исследования: Анализ возрастных диагностических и дефицитарных особенностей пациентов с МАЖБП. Материалы и методы: В исследование включено 25 пациентов с МАЖБП в возрасте 45-59 лет, 40 пациентов с МАЖБП в возрасте 60-74 лет и 20 человек с таким же заболеванием в возрасте 75 лет и старше. При обследовании всех пациентов выполнялись ультразвуковое исследование, эзофагогастродуоденоскопия, эластометрия печени и селезёнки, биохимический анализ крови. Оценка дефицитарного статуса выполнена по специальной программе для ЭВМ. Результаты: Показаны наибольшие различия между пациентами зрелого и пожилого возраста с наибольшим и статистически значимым превышением всех параметров у пациентов 60-74 лет с МАЖБП относительно лиц 45-59 лет, за исключением уровня тромбоцитов в крови, содержание которых было ниже у пациентов 60-74 лет (182,6&amp;plusmn;8,1 х109/л), чем в зрелом возрасте &amp;ndash; 205,4&amp;plusmn;7,3 х109/л (p&amp;lt;0,01). Среди пациентов пожилого возраста в 3,6 раза выше степень варикозного расширения вен пищевода, достигающая 1,8&amp;plusmn;0,1 против 0,5&amp;plusmn;0,2 (p&amp;lt;0,01), а также существенно выше показатель жёсткости печени &amp;ndash; 18,2&amp;plusmn;2,1 кПА против 9,4&amp;plusmn;1,5 кПа (p&amp;lt;0,01). Дефицитарный статус пациентов с МАЖБП пожилого возраста характеризуется субклинически выраженной депрессией (9,2&amp;plusmn;0,2 баллов), а лиц старческого возраста &amp;ndash; клинически выраженной депрессией (12,4&amp;plusmn;0,4 баллов) (p&amp;lt;0,05), умеренными когнитивными нарушениями (26,4&amp;plusmn;0,4 баллов) и лёгкой деменцией (22,6&amp;plusmn;0,3 баллов, p&amp;lt;0,05), синдромом старческой преастении в 12,5&amp;plusmn;2,1% и 35,0&amp;plusmn;2,9% (p&amp;lt;0,001), саркопенией в 22,5&amp;plusmn;1,8% и 30,0&amp;plusmn;2,4% соответственно (p&amp;lt;0,05). Заключение: Возрастными диагностическими особенностями МАЖБП являются повышенные показатели степени варикозного расширения вен пищевода, содержания в крови аспартатаминотрансферазы, жёсткости печени и сниженные уровни тромбоцитов в крови. Пациенты старческого возраста с МАЖБП относительно группы пожилого возраста с МАЖБП имеют более высокий уровень депрессии, когнитивных нарушений и распространённости синдрома старческой преастении. Данные параметры следует использовать в качестве ведущих диагностических критериев МАЖБП у пациентов пожилого и старческого возраста</p></abstract><trans-abstract xml:lang="en"><p>Background: Due to the growing elderly population and persistent nutritional misconceptions, the prevalence of metabolic-associated fatty liver disease (MAFLD) is rising. This condition can further worsen the geriatric health status of affected individuals. However, age-related diagnostic and deficiency features of MAFLD are currently insufficiently studied and contradictory. The aim of the study: An analysis of age-related diagnostic and deficiency features of patients with MAFLD. Materials and methods: The clinical study included 25 patients with MAFLD aged 45-59 years, 40 patients with MAFLD aged 60-74 years, and 20 people with the same disease aged 75 years and older. All patient age groups underwent a standardized evaluation protocol, including ultrasound examination, esophagogastroduodenoscopy (EGD), liver and spleen elastometry, measurement of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet levels, assessment of esophageal varices severity, and calculation of body mass index (BMI).The assessment of the deficiency status was performed using a special computer program with the identification of anxiety syndromes, depression, sarcopenia, senile preasthenia and cognitive impairment. The Statistica 10.0 program and the Correlation Analysis module were used for statistical processing. Results: The greatest differences in the studied diagnostic parameters were shown between mature and elderly patients, with the greatest and statistically significant excess of all parameters in patients aged 60-74 years with MAFLD relative to individuals aged 45-59 years, with the exception of the level of platelets in the blood, the content of which was lower in patients aged 60-74 years (182.6&amp;plusmn;8.1 x109/l) than in mature age &amp;ndash; 205.4&amp;plusmn;7.3 x109/l (p&amp;lt;0.01). Among elderly patients, the degree of esophageal varices is 3.6 times higher, reaching 1.8&amp;plusmn;0.1 versus 0.5&amp;plusmn;0.2 (p&amp;lt;0.01), and the liver stiffness index is also significantly higher &amp;ndash; 18.2&amp;plusmn;2.1 kPa versus 9.4&amp;plusmn;1.5 kPa (p&amp;lt;0.01), the aspartate aminotransferase content in the blood is 89.3&amp;plusmn;4.0 U/l versus 56.9&amp;plusmn;2.7 U/l (p&amp;lt;0.01), respectively. Less significant differences between these age groups were found in the spleen stiffness index and body mass index. Between elderly and senile patients with MAFLD, the differences were less pronounced than between the previous groups, but, as between patients 45-59 years old and 60-74 years old, the greatest differences were in the level of aspartate aminotransferase and esophageal varices. The deficiency status of elderly patients with MAFLD is characterized by subclinical depression (9.2&amp;plusmn;0.2 points), and in elderly individuals by clinically expressed depression (12.4&amp;plusmn;0.4 points) (p&amp;lt;0.05), moderate cognitive impairment (26.4&amp;plusmn;0.4 points) and mild dementia (22.6&amp;plusmn;0.3 points, p&amp;lt;0.05), senile preasthenia syndrome in 12.5&amp;plusmn;2.1% and 35.0&amp;plusmn;2.9% (p&amp;lt;0.001), sarcopenia in 22.5&amp;plusmn;1.8% and 30.0&amp;plusmn;2.4%, respectively (p&amp;lt;0.05). Conclusion: The age-related features of CKD include increased levels of esophageal varicose veins, blood levels of aspartate aminotransferase, liver stiffness, and decreased levels of platelets in the blood. Senile patients with CKD have higher levels of depression, cognitive impairment, and the prevalence of senile preasthenia gravis compared to the elderly group with CKD. These parameters should be used as the leading diagnostic criteria for CKD in elderly and senile patients</p></trans-abstract><kwd-group xml:lang="ru"><kwd>возрастные особенности</kwd><kwd>дефицитарный профиль</kwd><kwd>метаболически-ассоциированная жировая болезнь печени</kwd><kwd>комплексная гериатрическая оценка</kwd><kwd>диагностические параметры</kwd><kwd>гериатрическая помощь</kwd></kwd-group><kwd-group xml:lang="en"><kwd>age-related features</kwd><kwd>deficiency profile</kwd><kwd>metabolic-associated fatty liver disease</kwd><kwd>comprehensive geriatric assessment</kwd><kwd>diagnostic parameters</kwd><kwd>geriatric care</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. DOI: https://doi.org/10.1097/HEP.0000000000000323</mixed-citation></ref><ref id="B2"><mixed-citation>Riazi K, Azhari H, Charette J, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and metaanalysis. The Lancet Gastroenterology and Hepatology. 2022;7(9):851-861. DOI: https://doi.org/10.1016/s2468-1253(22)00165-0</mixed-citation></ref><ref id="B3"><mixed-citation>Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. DOI: https://doi.org/10.1097/HEP.0000000000000520</mixed-citation></ref><ref id="B4"><mixed-citation>De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII&amp;ndash;renewing consensus in portal hypertension. Journal of Hepatology. 2022;76(4):959-974. DOI: https://dx.doi.org/10.1016/j.jhep.2021.12.022</mixed-citation></ref><ref id="B5"><mixed-citation>Wong VWS, Ekstedt M, Wong GL, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. Journal of Hepatology. 2023;79(3):842-852. DOI: https://doi.org/10.1016/j.jhep.2023.04.036</mixed-citation></ref><ref id="B6"><mixed-citation>Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports. 2021;3(5):100322. DOI: https://dx.doi.org/10.1016/j.jhepr.2021.100322</mixed-citation></ref><ref id="B7"><mixed-citation>Selvaraj EA, Mozez FE, Jayaswal AN, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology. 2021;75(4):770-785. DOI: https://doi.org/10.1016/j.jhep.2021.04.044</mixed-citation></ref><ref id="B8"><mixed-citation>Vali Y, Lee J, Boursier J, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. The Lancet Gastroenterology and Hepatology. 2023;8(8):714-725. DOI: https://doi.org/10.1016/s2468-1253(23)00017-1</mixed-citation></ref><ref id="B9"><mixed-citation>Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. New England Journal of Medicine. 2021;385(17):1559-1569. DOI: https://doi.org/10.1056/nejmoa2029349</mixed-citation></ref><ref id="B10"><mixed-citation>Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and Management of Patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669. DOI: https://doi.org/10.1053/j.gastro.2021.07.049</mixed-citation></ref><ref id="B11"><mixed-citation>European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. Journal of Hepatology. 2021;75(3):659-689. DOI: https://doi.org/10.1016/j.jhep.2021.05.025</mixed-citation></ref><ref id="B12"><mixed-citation>Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and Management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice. 2022;28(5):528-562. DOI: https://doi.org/10.1016/j.eprac.2022.03.010</mixed-citation></ref><ref id="B13"><mixed-citation>Горелик СГ, Ильницкий АН, Прощаев КИ. Опросники и шкалы в геронтологии и гериатрии. Геронтология. 2021;1:1-88.</mixed-citation></ref><ref id="B14"><mixed-citation>Агарков НМ, Копылов АЕ. Влияние саркопенического ожирения, сочетанного с возраст-ассоциированными офтальмологическими заболеваниями, на деятельность в повседневной жизни. Российский журнал гериатрической медицины. 2024;19(3):202-208. DOI: https://doi.org/10.37586/2686-8636-3-2024-202-208</mixed-citation></ref><ref id="B15"><mixed-citation>Stefanescu H, Rusu C, Lupsor‐Platon M, et al. Liver stiffness assessed by ultrasound shear wave elastography from General Electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease. Ultraschall in der Medizin. 2020;41(5):526‐533. DOI: https://doi.org/10.1055/a-0965-0745</mixed-citation></ref><ref id="B16"><mixed-citation>Dajti E, Marasco G, Ravaioli F, et al. The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterology. 2021;67(2):151-163. DOI: https://doi.org/10.23736/s2724-5985.20.02793-2</mixed-citation></ref><ref id="B17"><mixed-citation>Abozaid YJ, Ayada I, van Kleef LA, et al.&amp;nbsp;Plasma Circulating Metabolites Associated With Steatotic Liver Disease and Liver Enzymes: A Multiplatform Population-Based Study.&amp;nbsp;Gastro Hep Advances. 2024;4(2):100551. DOI: https://doi.org/10.1016/j.gastha.2024.09.006</mixed-citation></ref><ref id="B18"><mixed-citation>Aggarwal K, Singh B, Goel A, et al.&amp;nbsp;Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities.&amp;nbsp;Intestinal Research. 2024;22(4):414-427. DOI: https://doi.org/10.5217/ir.2024.00001</mixed-citation></ref><ref id="B19"><mixed-citation>Mostafa AM, Hafez SM, Abdullah NM, et al. Fatigue, depression, and sleep disorders are more prevalent in patients with metabolic-associated fatty liver diseases. European Journal of Gastroenterology and Hepatology. 2024;36(5):665-673. DOI: https://doi.org/10.1097/MEG.0000000000002752</mixed-citation></ref><ref id="B20"><mixed-citation>Ismaiel A, Spinu M, Leucuta DC, et al. Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk. Journal of Clinical Medicine. 2022;11(9):2488. DOI: https://doi.org/10.3390/jcm11092488</mixed-citation></ref><ref id="B21"><mixed-citation>Li X, Xia X, Jiang B, et al. Higher serum chromium level may be associated with the presentation of depression in patients with metabolic dysfunction-associated fatty liver disease: evidence from NHANES survey. Frontiers in Psychiatry. 2024;15:1330283. DOI: https://doi.org/10.3389/fpsyt.2024.1330283</mixed-citation></ref><ref id="B22"><mixed-citation>Kaya E, Yilmaz Y. Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Cognitive Impairment and All-Cause Dementia: A Comprehensive Review. Turkish Journal of Gastroenterology. 2024;35(2):76-82. DOI: https://doi.org/10.5152/tjg.2024.23629</mixed-citation></ref><ref id="B23"><mixed-citation>Medina-Julio D, Ramirez-Mejia MM, Cordova-Gallardo J, et al. From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function. Medical Science Monitor. 2024;30:e943417-1&amp;ndash;e943417-13. DOI: https://doi.org/10.12659/MSM.943417</mixed-citation></ref><ref id="B24"><mixed-citation>Bali T, Chrysavgis L, Cholongitas E. Metabolic-Associated Fatty Liver Disease and Sarcopenia. Endocrinology and Metabolism Clinics of North America. 2023;52(3):497-508. DOI: https://doi.org/10.1016/j.ecl.2023.02.004</mixed-citation></ref><ref id="B25"><mixed-citation>Lossano MR, Parussolo ML, Silva AO, et al. Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia. International Journal of Molecular Sciences. 2025;26(10):4673. DOI: https://doi.org/10.3390/ijms26104673</mixed-citation></ref></ref-list></back></article>